The nuclear receptor FXR is expressed in pancreatic β-cells and protects human islets from lipotoxicity

被引：84

作者：

Popescu, Iuliana Ristea ^{[1
,2
,3
,4
]}

Helleboid-Chapman, Audrey ^{[1
,2
,3
,4
]}

Lucas, Anthony ^{[1
,2
,3
,4
]}

Vandewalle, Brigitte ^{[2
,4
,5
]}

Dumont, Julie ^{[1
,2
,3
,4
]}

Bouchaert, Emmanuel ^{[1
,2
,3
,4
]}

Derudas, Bruno ^{[1
,2
,3
,4
]}

Kerr-Conte, Julie ^{[2
,4
,5
]}

Caron, Sandrine ^{[1
,2
,3
,4
]}

Pattou, Francois ^{[2
,4
,5
]}

Staels, Bart ^{[1
,2
,3
,4
]}

机构：

[1] Inst Pasteur, INSERM, UMR1011, F-59019 Lille, France

[2] Univ Lille Nord France, F-59000 Lille, France

[3] INSERM, UMR1011, F-59000 Lille, France

[4] UDSL, F-59000 Lille, France

[5] CHRU Lille, INSERM, U859, Lab Diabet Cell Therapy, F-59000 Lille, France

来源：

FEBS LETTERS | 2010年 / 584卷 / 13期

关键词：

Farnesoid X receptor; Type; 2; diabetes; Islet; Lipotoxicity; FARNESOID-X-RECEPTOR; BILE-ACIDS; INSULIN SENSITIVITY; GLUCOSE; GENE; ACTIVATION; SECRETION; LIGANDS; MICE;

D O I：

10.1016/j.febslet.2010.04.068

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Farnesoid X receptor (FXR) is highly expressed in liver and intestine where it controls bile acid (BA), lipid and glucose homeostasis. Here we show that FXR is expressed and functional, as assessed by target gene expression analysis, in human islets and beta-cell lines. FXR is predominantly cytosolic-localized in the islets of lean mice, but nuclear in obese mice. Compared to FXR+/+ mice, FXR-/- mice display a normal architecture and b-cell mass but the expression of certain islet-specific genes is altered. Moreover, glucose-stimulated insulin secretion (GSIS) is impaired in the islets of FXR-/- mice. Finally, FXR activation protects human islets from lipotoxicity and ameliorates their secretory index. (C) 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

引用

页码：2845 / 2851

页数：7

共 29 条

[1] Synergistic activation of the insulin gene promoter by the β-cell enriched transcription factors MafA, Beta2, and Pdx1
Aramata, S
Han, S
Yasuda, K
Kataoka, K
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2005, 1730 (01): : 41 - 46
[2] Fibroblast Growth Factor-19, a Novel Factor That Inhibits Hepatic Fatty Acid Synthesis
Bhatnagar, Sushant
Damron, Holly A.
Hillgartner, F. Bradley
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (15) : 10023 - 10033
[3] The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice
Cariou, B
van Harmelen, K
Duran-Sandoval, D
van Dijk, TH
Grefhorst, A
Abdelkarim, M
Caron, S
Torpier, G
Fruchart, JC
Gonzalez, FJ
Kuipers, F
Staels, B
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (16) : 11039 - 11049
[4] Nuclear hormone receptor expression in the endocrine pancreas
Chuang, Jen-Chieh
Cha, Ji-Young
Garmey, James C.
Mirmira, Raghavendra G.
Repa, Joyce J.
[J]. MOLECULAR ENDOCRINOLOGY, 2008, 22 (10) : 2353 - 2363
[5] Glucose regulates the expression of the farnesoid X receptor in liver
Duran-Sandoval, D
Mautino, G
Martin, GV
Percevault, F
Barbier, O
Fruchart, JC
Kuipers, F
Staels, B
[J]. DIABETES, 2004, 53 (04) : 890 - 898
[6] Attenuation of FGF signalling in mouse β-cells leads to diabetes
Hart, AW
Baeza, N
Apelqvist, Å
Edlund, H
[J]. NATURE, 2000, 408 (6814) : 864 - 868
[7] Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray
Higashiyama, Hiroyuki
Kinoshita, Mine
Asano, Satoshi
[J]. ACTA HISTOCHEMICA, 2008, 110 (01) : 86 - 93
[8] Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis
Holt, JA
Luo, GZ
Billin, AN
Bisi, J
McNeill, YY
Kozarsky, KF
Donahee, M
Wang, DY
Mansfield, TA
Kliewer, SA
Goodwin, B
Jones, SA
[J]. GENES & DEVELOPMENT, 2003, 17 (13) : 1581 - 1591
[9] Temporal and quantitative correlations between insulin secretion and stably elevated or oscillatory cytoplasmic Ca2+ in mouse pancreatic β-cells
Jonas, JC
Gilon, P
Henquin, JC
[J]. DIABETES, 1998, 47 (08) : 1266 - 1273
[10] Insulin resistance and pancreatic β cell failure
Kasuga, Masato
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (07) : 1756 - 1760

← 1 2 3 →